Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.

* Context.--Programmed death ligand-1 (PD-L1) expression by tumors may enable them to avoid immunosurveillance. Objective.--To develop a PD-L1 immunohistochemical assay using the 22C3 anti-PD-L1 murine monoclonal antibody on the Dako platform as a possible companion diagnostic for pembrolizumab in p...

Descripción completa

Detalles Bibliográficos

Publicado en:	Archives of Pathology & Laboratory Medicine Vol. 140; no. 11; pp. 1243 - 1250
Autores principales:	Dolled-Filhart, Marisa, Roach, Charlotte, Toland, Grant, Stanforth, Dave, Jansson, Malinka, Lubiniecki, Gregory M., Ponto, Gary, Emancipator, Kenneth
Formato:	pictorial research tables/charts Journal Article
Publicado:	College of American Pathologists Nov2016
Acceso en línea:	Ver este registro en EBSCOhost